Welcome to our dedicated page for Karyopharm Therapeutics SEC filings (Ticker: KPTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Karyopharm Therapeutics Inc. (KPTI) SEC filings page provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Karyopharm is a commercial-stage pharmaceutical company listed on the Nasdaq Global Select Market, and its filings detail financial results, financing arrangements and key corporate developments related to its oncology-focused business.
Among the most relevant documents for investors are Form 10-K annual reports and Form 10-Q quarterly reports, which summarize financial performance, risk factors and updates on Karyopharm’s commercial product XPOVIO (selinexor) and its clinical pipeline in multiple myeloma, endometrial cancer, myelofibrosis and diffuse large B-cell lymphoma (DLBCL). These periodic reports typically discuss revenue from U.S. XPOVIO net product sales and license and royalty revenue from partners, as described in the company’s public communications.
The company also files numerous Form 8-K current reports to describe material events. Recent 8-K filings referenced in the provided information include disclosures of quarterly financial results, strategic financing transactions involving senior secured term loans and 9.00% convertible senior notes due 2028 and 2029, and the issuance of equity and warrants in private placements. Other 8-Ks cover topics such as board changes, workforce reductions and the provision of “cleansing materials” to potential investors during financing discussions.
Investors tracking capital structure and liquidity can review exhibits to these filings, which describe credit and guaranty agreements, note purchase agreements, warrant terms and registration rights agreements. For governance and compensation matters, additional filings may include proxy statements and equity award disclosures, such as inducement grants reported under Nasdaq Listing Rule 5635(c)(4).
On this page, Stock Titan supplements raw EDGAR documents with AI-powered summaries that highlight the main points of lengthy filings, helping readers quickly understand changes in debt, equity, cash runway expectations, and updates on Karyopharm’s clinical and commercial programs. Real-time updates ensure that new 10-Ks, 10-Qs, 8-Ks and other forms appear as they are filed, while specialized views can surface insider-related forms such as Form 4 when available.
T. Rowe Price Investment Management, Inc. filed an amended Schedule 13G reporting beneficial ownership of 2,244,421 shares of THERAPEUTICS INC common stock, representing 11.8% of the class as of the event date December 31, 2025.
The firm reports sole voting and dispositive power over 1,491,409 shares and no shared voting or dispositive power. It states that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control, and expressly denies beneficial ownership beyond what is required to be reported.
Karyopharm Therapeutics reports 2025 revenue of
Cash, cash equivalents and investments were
To gain liquidity, Karyopharm completed October 2025 financing transactions that added
Adage Capital Management and related principals report a 2.38% stake in Karyopharm Therapeutics Inc. common stock. The Reporting Persons beneficially own 436,736 shares, including 15,414 shares issuable upon exercise of warrants. This percentage is based on 18,310,283 shares outstanding as of December 29, 2025.
They state the holdings are maintained in the ordinary course of business and not for the purpose of changing or influencing control of Karyopharm. All voting and dispositive power over these shares is shared among the Reporting Persons, with no sole voting or dispositive authority reported.
Karyopharm Therapeutics reported essentially flat 2025 revenue while remaining deeply loss-making and heavily leveraged. Total revenue was $146.1 million, up slightly from $145.2 million, with U.S. XPOVIO net product revenue of $114.9 million. Loss from operations improved to $90.7 million from $119.4 million as R&D and SG&A were reduced, but net loss widened sharply to $196.0 million, driven largely by a $62.4 million loss on extinguishment of debt and higher interest expense.
Cash, cash equivalents, restricted cash and investments fell to $64.1 million at year-end 2025, and the company expects its existing liquidity plus cash flows to fund operations only into the second quarter of 2026. For 2026, Karyopharm guides total revenue to $130–$150 million and U.S. XPOVIO net product revenue to $115–$130 million, against planned R&D and SG&A of $230–$245 million, implying continued operating losses.
Strategically, management highlights late-stage pipeline catalysts: top-line data from the Phase 3 SENTRY myelofibrosis trial expected in March 2026, and top-line data from the Phase 3 XPORT-EC-042 endometrial cancer trial expected in mid-2026, positioning 2026 as a pivotal year for selinexor’s potential label and revenue expansion.
Karyopharm Therapeutics Inc. received a Schedule 13G filing showing that hedge fund–related entities have become significant shareholders of its common stock.
Integrated Core Strategies (US) LLC reports beneficial ownership of 997,577 shares, or 5.4% of the common stock. Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each report beneficial ownership of 1,008,662 shares, or 5.5% of the class, with shared voting and dispositive power and no sole authority.
The filers certify that the shares were not acquired to change or influence control of Karyopharm, but instead are held on a passive investment basis.
Karyopharm Therapeutics Inc. reported that its President and CEO, Richard A. Paulson, received an award of 81,060 shares of common stock in the form of restricted stock units (RSUs) on February 5, 2026. The RSUs were granted at $0 per share under the company’s 2022 Equity Incentive Plan and increase his directly held beneficial ownership to 279,391 shares of common stock.
The RSUs convert into common stock on a one-for-one basis. Vesting is scheduled so that 50% of the RSUs vest on January 31, 2027, with the remaining 50% vesting on January 31, 2028, tying a portion of the CEO’s compensation to the company’s long-term performance and continued service.
Karyopharm Therapeutics executive Lori Macomber reported an automatic tax-related stock sale. On 02/03/2026, the EVP, CFO & Treasurer sold 1,626 shares of Karyopharm Therapeutics Inc. common stock at $6.30 per share in a broker-assisted transaction tied to restricted stock unit vesting. After the sale, she directly beneficially owned 85,105 common shares. The filing explains the transaction was executed under a durable automatic sale instruction plan adopted on December 19, 2024, solely to cover withholding tax liabilities and did not represent a discretionary trade.
Karyopharm Therapeutics Inc. executive Sohanya Cheng, EVP & Chief Commercial Officer, received an award of 32,415 shares of common stock in the form of restricted stock units on January 31, 2026. The RSUs were granted at $0 per share under the company’s 2022 Equity Incentive Plan.
The RSUs convert into common stock on a one-for-one basis, with 50% vesting on January 31, 2027 and the remaining 50% vesting on January 31, 2028. Following this grant, Cheng beneficially owns 111,921 shares of Karyopharm common stock in direct ownership.
Karyopharm Therapeutics reported that its EVP & Chief Medical Officer, Reshma Rangwala, received an award of 32,415 restricted stock units (RSUs) of common stock on January 31, 2026 at a price of $0 per share. The RSUs were granted under the company’s 2022 Equity Incentive Plan and convert into common stock on a one-for-one basis. Half of the shares vest on January 31, 2027, with the remaining half vesting on January 31, 2028. Following this award, Rangwala beneficially owns 61,805 shares of Karyopharm common stock directly.
Karyopharm Therapeutics Inc. reported an equity compensation award to its EVP, CFO & Treasurer, Lori Macomber. She received 32,415 restricted stock units (RSUs)$0.
The RSUs convert into common stock on a one-for-one basis. They vest in two equal installments, with 50% vesting on January 31, 2027 and the remaining 50% on January 31, 2028. Following this grant, Macomber beneficially owns 86,731 shares of Karyopharm common stock.